Tag:
Heplisav
Latest Headlines
Latest Headlines
NIAID awards $46.3 million in vax grants and contracts
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded two grants to vaccine makers for anthrax and hepatitis B vaccines, respectively. Emergent BioSolutions received a
Dynavax shares spike on promising Heplisav data
Shares of Dynavax Technologies soared 35 percent after the developer announced that its hepatitis B vaccine Heplisav produced promising data in a mid-stage study, protecting patients with chronic
Dynavax's hep B vax Heplisav appears as safe as GSK's new jab
Shares of Dynavax Technologies (DVAX) spiked 21 percent this morning after the developer announced that its experimental hepatitis B vaccine Heplisav proved to be as safe as GSK's recently approved
Dynavax gets green light to resume hep B vax program
The FDA is giving Dynavax Technologies a green light to resume testing of a late-stage hepatitis B vaccine that had been derailed 18 months ago after a patient in one study developed a rare
Dynavax shares soar as FDA clears hep B trial
Over at FierceVaccines this morning, we take a look at several key biotech developments. Dynavax Technologies' shares soared 75 percent after the FDA lifted its clinical hold on the developer's
Dynavax explores new strategy for Heplisav
Dynavax Technologies has been talking with regulators in Europe about the potential for developing Heplisav, an experimental hepatitis B vaccine, for people over 40 who aren't responding to currently
Dynavax tanks on feds' Heplisav stance
Shares of Dynavax Technologies plunged 75 percent after company officials announced that U.S. regulators were asking for more information on its hepatitis B Vaccine and was
Merck, Dynavax announce Heplisav results
Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed
Merck, Dynavax announce Heplisav results
Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed
Dynavax shares hammered on FDA clinical hold
Dynavax's shares took a beating this morning after the FDA placed a clinical hold on the company's trial of Heplisav, a hepatitis B therapy. According to the Motley Fool, "[t]he agency put the
